Neutrophil/lymphocyte ratio is associated with survival in synovial sarcoma

García-Ortega, Dorian Yarih; Álvarez-Cano, Alethia; Sánchez-Llamas, Luis Adolfo; Caro-Sánchez, Claudia Haydeé Saraí; Martínez-Said, Héctor; Luna-Ortiz, Kuauhyama; Cuéllar-Hübbe, Mario

doi:10.1016/j.suronc.2018.07.012

Cited by 19 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accurately identifying patients with a high risk of recurrence is crucial for improving prognosis, as these patients might benefit from early adjuvant chemotherapy or targeted therapy with a more frequent follow-up. Previously, studies have found several indexes, including age, tumor size and preoperative NLR, as effective predictors for evaluating the relapse of TGCTs (26), SS (27,28) or other highly recurrent neoplasms (29,30). In our research, we found that the age of onset and preoperative NLR were both strongly associated with the long-term prognosis of d-TGCTs.…”

Section: Discussionsupporting

confidence: 60%

Clinical comparison of tenosynovial giant cell tumors, synovial chondromatosis, and synovial sarcoma: analysis and report of 53 cases

Wang¹,

Long²,

Wei³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: Tenosynovial giant cell tumors (TGCTs), synovial chondromatosis (SC), and synovial sarcoma (SS) exhibit similarities in clinical features and histochemical characteristics, and differential diagnosis remains challenging in clinical practice.Methods: Data were collected from the pathology database of Shanghai Ninth People's Hospital regarding patients who underwent surgery from 2010 to 2019 with histologically confirmed TGCTs, SC, and SS.Demographic and clinicopathological data of these patients were reviewed. Immunohistochemistry staining of 14 different markers was performed. Correlation analyses of the prognoses were evaluated.Results: A total of 26 patients with TGCTs (8 diffuse TGCTs and 18 localized TGCTs), 16 with SC, and 11 with SS were identified. Pain was the main symptom of patients with both TGCTs and SC, while a palpable mass was the most common symptom for patients with SS. In addition to clinical features, we identified vital risk factors for disease recurrence. The mean follow-up periods were 51, 39, and 14 months for TGCTs, SC, and SS, respectively. Younger patients with diffuse TGCTs or patients with a higher neutrophil/lymphocyte ratio (NLR) displayed a significantly higher frequency of recurrence. We also plotted receiver operating characteristic (ROC) curve analysis for age and NLR. The area under the ROC curve (AUC) was calculated and demonstrated the ability to distinguish recurrent from nonrecurrent cases. In addition, higher CD163 expression was linked to recurrent diffuse TGCT cases. Conclusions: These data indicated possible characteristics of different aspects of TGCTs, SC, and SS.Further clarification and understanding of these factors will help with differential clinical diagnosis and recurrent risk assessment.

show abstract

Section: Discussionsupporting

confidence: 60%

Clinical comparison of tenosynovial giant cell tumors, synovial chondromatosis, and synovial sarcoma: analysis and report of 53 cases

Wang¹,

Long²,

Wei³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…Not only individual inflammatory markers, such as CRP, and lymphocytes, but also combination of them, such as NLR, PLR and LMR, have been investigated in STSs (20, 22, 25, 26). NLR was found to be a prognostic inflammatory index for synovial sarcoma (SS) (23, 24). In addition, the overall survival of SS still remains unsatisfying (27).…”

Section: Discussionmentioning

confidence: 99%

“…Recent years, several studies have focused on prognostic factors for synovial sarcoma. High NLR was found to be a reliable prognostic factor which was associated with worse survival for synovial sarcoma patients (23, 24).…”

Section: Introductionmentioning

confidence: 96%

Pretreatment Inflammatory Indexes as Prognostic Predictors of Survival in Patients Suffering From Synovial Sarcoma

Yuan

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

Background: Inflammatory indexes have been considered as important prognostic factors in various types of cancers. This study aimed to evaluate prognostic values of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) in patients with synovial sarcoma (SS).Methods: One hundred and three patients diagnosed with SS were collected during 2006–2017 and divided into high or low NLR, PLR, and LMR groups based on receiver operating characteristic curve analysis. Data of clinical variables were collected for univariate and multivariate analyses. The Kaplan–Meier method was used to analyze OS and PFS of SS patients and significance was evaluated by the log-rank test.Results: The optimal cut-off values of NLR, PLR, and LMR were 2.70, 154.99, and 4.16, respectively. Univariate analyses identified resection surgery, distant metastasis, NLR, PLR, and LMR as the potential predictors of progression-free survival (PFS) and overall survival (OS). In the multivariate analyses, NLR was independent predictors for OS (HR 5.074, 95% CI 1.200–21.463, p = 0.027). Resection surgery, metastasis and LMR was independent predictors for PFS (HR 5.328, p = 0.017; HR 3.114, p = 0.04 and HR 0.202, p = 0.025, respectively).Conclusion: Resection surgery, distant metastasis, NLR, and LMR were independent prognostic factors of PFS and OS in patients with synovial sarcoma. Surgery as an effective treatment strategy, other than radiotherapy and chemotherapy, can significantly prolong survival of synovial patients. Clinical utility of these inflammatory biomarkers should be validated in a larger sample size study.

show abstract

“…Lymphocyte plays prominent role in the tumor related immunity, which contribute to host defense [ 21 , 22 , 23 , 24 ]. Therefore, lymphocyte related prognostic tools, such as neutrophil to lymphocyte ratio and platelet to lymphocyte ratio, were reported in patients with STS [ 25 , 26 , 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?

Nakamura

Hagi

Asanuma

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Recently, the lymphocyte-to-CRP ratio (LCR) was found to have a prognostic role in many cancers. However, the clinical significance of LCR in patients with soft tissue sarcoma (STS) has not yet been established. This study aimed to determine whether LCR can predict disease-specific survival (DSS) and event-free survival (EFS) in patients with STS. Methods: In this study, 132 patients were enrolled. The mean follow-up periods were 76.5 months. Blood examinations were performed prior to treatment for all patients. Results: The 5-year DSS in patients with higher and lower LCR was 86.5% and 52.8%, respectively (p < 0.001). Patients with lower LCR had worse survival than those with higher LCR. The 5-year EFS in patients with higher and lower LCR was 66.2% and 31.2%, respectively (p < 0.001). On Receiver operating characteristic analysis, however, there was no significant difference in the area under curve (AUC) between CRP level (AUC = 0.72) and LCR (AUC = 0.711). Conclusions: LCR may be a prognostic factor for predicting oncological events in multivariate analysis, although ROC analysis could not show the superiority of LCR to CRP for predicting oncological outcomes in patients with STS.

show abstract

Neutrophil/lymphocyte ratio is associated with survival in synovial sarcoma

Cited by 19 publications

References 20 publications

Clinical comparison of tenosynovial giant cell tumors, synovial chondromatosis, and synovial sarcoma: analysis and report of 53 cases

Clinical comparison of tenosynovial giant cell tumors, synovial chondromatosis, and synovial sarcoma: analysis and report of 53 cases

Pretreatment Inflammatory Indexes as Prognostic Predictors of Survival in Patients Suffering From Synovial Sarcoma

Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?

Contact Info

Product

Resources

About